Government,
Civil Litigation
Oct. 26, 2020
Purdue deal puts damages payouts on uncharted path
The privately held drug company would emerge from bankruptcy as a public benefit corporation managed by a trust. Such a corporate structure is not extraordinary, as it attempts to balance making a profit with serving the public.
The federal government's settlement with Purdue Pharma LP, maker of OxyContin, will attempt to repay government agencies and individual plaintiffs for damages caused by the opioid with a corporate entity never before used this way.
The privately held drug company would emerge from bankruptcy as a public benefit corporation managed by a trust. Such a corporate structure is not extraordinary, as it attempts to balance making a profit ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In